Soaring Demand Set to Propel Biomarkers Market to $131.78 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Biomarkers Market Through 2025?
In recent years, the size of the biomarkers market has experienced rapid expansion. Projections indicate that it will increase from $68.77 billion in 2024 to $77.42 billion in 2025, representing a compound annual growth rate (CAGR) of 12.6%. This growth during the historical period has been driven by developments in genomics and proteomics technologies, an increased prevalence of chronic illnesses, a heightened focus on personalized medicine, a surge in demand for companion diagnostics, and the expanded use of applications in drug development.

What's the Projected Size of the Global Biomarkers Market by 2029?
The biomarkers market is projected to experience a swift expansion in the coming years, with an estimated growth to $131.78 billion by 2029, at a compound annual growth rate (CAGR) of 14.2%. The anticipated growth during the prediction period is mainly driven by the increasing concentration on early disease diagnosis and prevention, the widening application of biomarkers in oncology and immunotherapy, heightened investment into precision medicine initiatives, the emerging popularity of liquid biopsy as a non-invasive method to detect biomarkers, and progressively favoring biomarkers in pharmaceutical discovery and development. Significant trends predicted for the forecast period include the advancement of multi-biomarker panels, the rise of exosome-based biomarkers, the increasing adoption of point-of-care biomarker testing, the integration of real-world data into biomarker research, and the investigation into microbiome-based biomarkers.

View the full report here:
https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Top Growth Drivers in the Biomarkers Industry: What's Accelerating the Market?
The rise in cardiovascular disorders is anticipated to spur the expansion of the biomarkers market during the projected period. There has been a significant surge in the usage of biomarkers for cardiovascular patients in recent years. Currently, natriuretic peptides are the most employed biomarkers, aiding in the diagnosis of individuals suffering from heart failure. High sensitivity C-reactive protein, a type of circulating biomarker, is utilized for diagnosing heart failure. Heart diseases are among the primary causes of death across most racial and ethnic groups in the United States, resulting in a heightened demand for biomarkers. In August 2022, as per a report from the American College of Cardiology, a not-for-profit medical association based in the U.S, a growth is predicted across all four cardiovascular risk factors between 2025 and 2060. Diabetes is anticipated to see the highest increase of 39.3% affecting 55 million individuals, followed by dyslipidemia with a 27.6% increase to 126 million, hypertension at 25.1% to 162 million, and obesity at 18.3% to 126 million. The report also noted projected surges in rates of cardiovascular diseases, with the largest being stroke at 33.8% to 15 million and heart failure at 33.4% to 13 million, followed by ischemic heart disease at 30.7% to 29 million and heart attack at 16.9% to 16 million. Consequently, the escalating rates of heart diseases and fatalities will result in enhanced growth of the biomarkers market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6485&type=smp

What Trends Will Shape the Biomarkers Market Through 2029 and Beyond?
Big firms in the biomarker market are centering their attention on fostering innovative solutions such as creating a unique biological marker to propel innovation through joint research endeavors, combining technology, and solid clinical verification. A unique biological marker represents a freshly discovered signifier that mirrors biological mechanisms and assists in detecting or overseeing illnesses. It could be a molecule, gene, or cellular attribute carrying notable implications for individualized medicine. For instance, Genialis, an American computational precision medicine enterprise, in September 2024, initiated a maiden biomarker of its kind. This ground-breaking biomarker bolsters the predictive precision of patient reactions to KRAS inhibitors, thus facilitating customized treatment strategies and enhancing clinical results. Its wide usage across different cancer types encourages efficient medication development and improves patient selection for targeted therapies.

What Are the Main Segments in the Biomarkers Market?
The biomarkers market covered in this report is segmented -

1) By Technology: Safety Biomarkers, Efficacy Biomarkers, Validation Biomarkers
2) By Disease: Neurological Diseases, Cancer, Immunological Diseases, Cardiovascular Diseases, Other Diseases
3) By Type: Biomarker Of Exposure, Biomarker Of Diseases
4) By Audiences: Pharmaceutical Companies, Government And Private Research Institutes, Academic Institutes, Medical Device Manufacturing Companies

Subsegments:
1) By Safety Biomarkers: Toxicity Biomarkers, Pharmacokinetic Biomarkers, Adverse Effect Biomarkers
2) By Efficacy Biomarkers: Pharmacodynamic Biomarkers, Disease Progression Biomarkers, Treatment Response Biomarkers
3) By Validation Biomarkers: Analytical Validation Biomarkers, Clinical Validation Biomarkers, Qualification Biomarkers

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=6485&type=smp

Which Top Companies are Driving Growth in the Biomarkers Market?
Major companies operating in the biomarkers market include Enzo Biochem Inc, Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., QIAGEN N. V., Adaptive Biotechnologies Corp., Agilent Technologies Inc., Biocrates Life Sciences AG, BioFire Diagnostics LLC, BioReference Laboratories Inc., Bio-Techne Corporation, Cepheid Inc., Eurofins Scientific SE, Exact Sciences Corporation, Foundation Medicine Inc., Genomic Health Inc., GenScript Biotech Corporation, Guardant Health Inc., Illumina Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Luminex Corporation, Metabolon Inc., Myriad Genetics Inc., Natera Inc., Pacific Biosciences of California Inc., Quest Diagnostics Incorporated, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Veracyte Inc.

Which Regions Will Dominate the Biomarkers Market Through 2029?
North America was the largest region in the biomarkers market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6485

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Speak With Our Expert:
Saumya Sahay
Americas +1 310-496-7795,
Asia +44 7882 955267 & +91 8897263534,
Europe +44 7882 955267
Email:saumyas@tbrc.info
The Business Research Company -www.thebusinessresearchcompany.com
Follow Us On:
LinkedIn:https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.